✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
Leuk Lymphoma 1996;21:391-397.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Darbaş Ş, Aydın Ç, Salim O, Berker Karaüzüm S.
📊
Key Findings & Data:Investigation of MDM2oncogene copy number alterations in cases of chronic lymphocyticleukemia.
💡
Conclusion & Impact:Leuk Lymphoma 1996;21:391-397.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters
Özet
1. Darbaş Ş, Aydın Ç, Salim O, Berker Karaüzüm S. Investigation of MDM2oncogene copy number alterations in cases of chronic lymphocyticleukemia. Turk J Hematol 2019;36:126-127.2. Bixby D, Kujawski L, Wang S, Malek SN. The pre-clinical development ofMDM2 inhibitors in chronic lymphocytic leukemia uncovers a central rolefor p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. CellCycle 2008;7:971-979.3. Watanabe T, Ichikawa A, Saito H, Hotta T. Overexpression of the MDM2oncogene in leukemia and lymphoma. Leuk Lymphoma 1996;21:391-397.
🔖
Cite This Article
SOOKAROMDEE, P., WIWANITKIT, V. (2019). MDM2 Oncogene Copy Number Alterations in Chronic Lymphocytic Leukemia. Turkish Journal of Hematology, Cilt: 36 - Sayı: 3, 220–220. https://ajindex.com/articles/412722